Abstract:OBJECTIVE:The study was designed to investigate the changes in CD(69), CD(25) and HLA-DR expressions in peripheral blood T cell in Kawasaki disease (KD). METHODS:The authors detected CD(69), CD(25) and HLA-DR expressions in peripheral blood T cell by using flow cytometry. The patients who met the diagnostic criteria for KD comprised sixteen boys and fifteen girls (4 - 60 months of age; mean, 26 +/- 18 months). All received intravenous gammaglobulin at a dose of 1 g/(kg.d), for 2 days and oral aspirin at a dose of 30 - 50 mg/(kg.d). In case of persistent fever, a repeated dose of intravenous gammaglobulin or I.V. methylprednisolone at a dose of 20 mg/(kg.d) for three daily doses was attempted. The authors tested blood samples from 17 healthy controls consisting of nine boys and eight girls (3 - 84 months of age; mean, 25 +/- 18 months) and the samples from 31 patients. RESULTS:The percentage of peripheral blood CD(3)(+) T lymphocyte was (54.4 +/- 9.0)% in acute stage of KD and (65.0 +/- 7.0)% in healthy controls. There was a significant difference between the two groups (P < 0.001). The values of CD(69)(+) [(11.2 +/- 12.6)%, vs. (0.6 +/- 0.4)%], CD(25)(+) [(9.2 +/- 3.5)% vs. (3.9 +/- 1.8)%] and HLA-DR(+) [(8.3 +/- 5.0)% vs. (4.3 +/- 2.3)%] in KD patients were markedly increased compared to those of the healthy controls. After intravenous gammaglobulin treatment, the percentage of CD(3)(+)CD(69)(+) and CD(3)(+)CD(25)(+) significantly decreased [CD(3)(+)CD(69)(+): (14.0 +/- 13.0)% vs. (1.6 +/- 1.2)%, P < 0.05; CD(3)(+)CD(25)(+): (7.8 +/- 4.1)% vs. (2.0 +/- 0.6)%, P < 0.01]. However, the CD(3)(+) T lymphocytes increased [(50.8 +/- 5.0)% vs. (64.9 +/- 5.5)%, P < 0.01]. There was no significant difference in expression of CD(3)(+) T lymphocyte cell activating markers between coronary artery disease group and normal coronary artery group in KD cases (P > 0.05). CONCLUSION:CD(3)(+) T cell activation in the early and middle stages is involved in the mechanism responsible for cardiovascular injury.

Molecular mechanisms of endothelial dysfunction in Kawasaki-disease-associated vasculitis

Relationship of endothelial cell dysfunction and the coronary lesions of Kawasaki disease

Regulatory T cells and Kawasaki disease

Molecular Mechanisms and Therapeutic Strategies in Kawasaki Disease

Hypercoagulation and elevation of blood triglycerides are characteristics of Kawasaki disease

The Therapeutic Effects of EFNB2-Fc in a Cell Model of Kawasaki Disease.

Changes in CD_(69),CD_(25) and HLA-DR Expressions in Peripheral Blood T Cells in Kawasaki Disease

The Network of Pro-Inflammatory Factors CD147, DcR3, and IL33 in the Development of Kawasaki Disease.

Assessment of vascular and endothelial function in Kawasaki disease

The role of Ca 2+ /NFAT in Dysfunction and Inflammation of Human Coronary Endothelial Cells induced by Sera from patients with Kawasaki disease

Study Progress of Coronary Artery Damage in Kawasaki Disease

Emerging evidence of microbial infection in causing systematic immune vasculitis in Kawasaki disease

The up‐to‐date pathophysiology of Kawasaki disease

Markers of Endothelial Dysfunction in Kawasaki Disease: An Update

Platelet-Monocyte Aggregate Instigates Inflammation and Vasculopathy in Kawasaki Disease

Advances in research of the relationship between adhesion molecules and pathogenesis of Kawasaki disease

Preventing coronary artery lesions in Kawasaki disease

Single-Cell Transcriptome Reveals Potential Mechanisms for Coronary Artery Lesions in Kawasaki Disease

Potential roles of NLRP3 inflammasome in the pathogenesis of Kawasaki disease

Non‐coding RNAs in Kawasaki disease: Molecular mechanisms and clinical implications

The Role of Circulating Immune Complexes in Coronary Artery Lesions: Understanding possible Patho-Physiology in Kawasaki Disease Revisited